The top after-market NASDAQ stock market gainers are: Neurocrine Biosciences, Leap Wireless International, Winn-Dixie Stores, NPS Pharmaceuticals, and Canadian Solar. The top after-market NASDAQ stock market losers are: Exelixis, Powerwave Technologies, Cavium, Cadiz, and GeoEye.
Neurocrine Biosciences Inc. (NBIX) stock jumped 11.82 percent to $7 in after-market trading. Profit for the third quarter was $31.4 million or $0.56 per share, higher than last year's $3.3 million or $0.06 per share. Revenue grew to $41.6 million from $14.4 million. Analysts expected profit of $0.19 per share on revenue of $21.64 million. The company recognized a $10 million milestone, relating to the transition of Elagolix into Phase 2 clinical trials for Uterine Fibroids and a $20 million milestone relating to the outcome of an Elagolix pre-Phase 3 meeting with the FDA for Endometriosis.
Leap Wireless International Inc. (LEAP) stock climbed 11.22 percent to $7.73 in after-market trading. Loss for the third quarter narrowed to $68.8 million or $0.90 per share from $536.3 million or $7.06 per share last year. Results for the previous year included an impairment charge of $477.3 million related to goodwill and other assets. Revenue grew 19.6 percent to $763.3 million. Analysts expected a loss of $0.79 per share on revenue of $763.63 million.
Winn-Dixie Stores Inc. (WINN) stock grew 8.36 percent to $6.87 in after-market trading. Loss for the first quarter narrowed to $24.1 million or $0.43 per share from $76.8 million or $1.39 per share last year. Loss from continuing operations narrowed to $24.6 million or $0.44 per share from $36.5 million or $0.66 per share. Sales rose to $1.59 billion from $1.54 billion. Analysts expected a loss of $0.42 per share on revenue of $1.60 billion. Looking ahead into fiscal 2012, the company reaffirmed its adjusted EBITDA outlook of $120 million to $135 million. The company also anticipates not having to pay incomes taxes in fiscal 2012 due to the sufficiency of its tax-loss carry-forwards.
NPS Pharmaceuticals Inc. (NPSP) stock gained 6.46 percent to $5.27 in after-market trading.
Canadian Solar Inc. (CSIQ) stock increased 5.22 percent to $3.63 in after-market trading.
Exelixis Inc. (EXEL) stock plunged 35.32 percent to $5 in after-market trading. The company said it had decided to initiate the '306 trial by the end of 2011, without waiting for or no longer pursuing a Special Protocol Assessment (SPA). The company failed to reach a timely agreement under an SPA with the U.S. Food and Drug Administration on the proposed design and analysis of the '306 trial. Based on regulatory feedback obtained from both the FDA and European Medicines Agency to date, the company has determined that pain will be the primary efficacy endpoint for the trial.
The double-blind '306 trial is designed to enroll 246 patients with CRPC metastatic to bone, who are suffering from moderate to severe bone pain despite optimized narcotic medication, and who have failed prior treatment with docetaxel and abiraterone in no particular order. The '306 trial will be conducted in English speaking regions including the United States, Canada and the United Kingdom. Patients will be randomized 1:1 to receive either cabozantinib or mitoxantrone/prednisone. Alleviation of bone pain will be the primary endpoint, and will be measured by comparing the percentage of patients in the two treatment arms who achieve a pain response at week 9 that is confirmed at week 15.
The company had previously communicated a comprehensive development plan and regulatory strategy in metastatic CRPC that includes a pivotal trial focused on overall survival, consistent with the FDA's feedback in connection with the SPA process related to the '306 trial. In that context, the company plans to initiate its Phase 3 '307 trial in the first half of 2012. The '307 trial is expected to be a global trial powered to evaluate overall survival time, comparing cabozantinib versus prednisone in patients who have failed prior docetaxel and abiraterone. Cabozantinib is a potent inhibitor of MET and VEGFR2 that inhibits tumor growth, metastasis and angiogenesis in preclinical models. MET is up-regulated in many tumor types and promotes tumor cell survival, invasion and metastasis.
Powerwave Technologies, Inc. (PWAVD) stock fell 9.42 percent to $3.27 in theafter-market trading.
Cavium Inc. (CAVM) stock tumbled 8.23 percent to $30 in after-market trading. Profit for the third quarter was $6.0 million or $0.12 per share, up from $5.0 million or $0.10 per share last year. Adjusted earnings were $14.4 million or $0.27 per share. Revenue grew 22.7 percent to $67.7 million. Analysts expected profit of $0.26 per share on revenue of $68.19 million.
Cadiz Inc. (CDZI) stock slid 8.08 percent to $9.61 in after-market trading.
GeoEye Inc. (GEOY) stock declined 7.66 percent to $31 in after-market trading. Adjusted profit for the third quarter was $11.7 million or $0.51 per share, down from $13.6 million or $0.61 per share last year. Revenue marginally declined 0.8 percent to $85.77 million. Analysts expected profit of $0.56 per share on revenue of $93.01 million.
Looking ahead to the fourth quarter, the company expects revenue of $88 million to $95 million, while Wall Street predicts $101.44 million. For the full year 2011, the company lowered its earnings guidance to range of $1.95 to $2.15 per share from previous forecast of $2.00 to $2.25 per share. The company also reduced its 2011 revenue outlook to range between $348 million and $355 million, from the previous range of $365 million to $375 million. Street analysts predict profit of $2.19 per share on revenue of $369.56 million for the fiscal 2011.